Preclinical data suggested that anti-angiogenic agents could increase CD8+ T cell infiltration and enhance the anti-tumor activity of CD8+ T cell by upregulating the expression of PD-L1, reducing immunosuppressive cells (TAMs, Tregs), and enhancing interactions between APCs and dendritic cells 59-61. This evidence concerns the gene CD8A and neoplasm.